Growth hormone deficiency and replacement effect on adult bone mass

A clinical update

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Patients with growth hormone (GH) deficiency have decreased bone mineral density (BMD) and higher risk of fractures. Younger age, severe GHD, longer period of interruption of GH treatment before achievement of peak bone mass, un-replaced sex steroids or over replacement of glucocorticoid or thyroid deficiencies may contribute to lower BMD in GHD patients. Positive BMD change has been noted in prospective trials after at least a year of GH replacement and may persist for up to 10–15 years with continued treatment. Males and patients with more severe bone loss often respond with better increases in BMD. Growth hormone replacement may decrease risk of fractures, especially in non-osteoporotic adults; however, randomized controlled trials are needed to rigorously assess fracture benefit.

Original languageEnglish (US)
Pages (from-to)7-20
Number of pages14
JournalCurrent Opinion in Endocrine and Metabolic Research
Volume3
DOIs
StatePublished - Dec 1 2018

Fingerprint

Bone Density
Growth Hormone
Bone and Bones
Glucocorticoids
Thyroid Gland
Randomized Controlled Trials
Steroids
Therapeutics

Keywords

  • Adult
  • Bone mass
  • Bone mineral density
  • Growth hormone
  • Growth hormone deficiency

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

@article{e0dd953234894f62895a856faf85a9b8,
title = "Growth hormone deficiency and replacement effect on adult bone mass: A clinical update",
abstract = "Patients with growth hormone (GH) deficiency have decreased bone mineral density (BMD) and higher risk of fractures. Younger age, severe GHD, longer period of interruption of GH treatment before achievement of peak bone mass, un-replaced sex steroids or over replacement of glucocorticoid or thyroid deficiencies may contribute to lower BMD in GHD patients. Positive BMD change has been noted in prospective trials after at least a year of GH replacement and may persist for up to 10–15 years with continued treatment. Males and patients with more severe bone loss often respond with better increases in BMD. Growth hormone replacement may decrease risk of fractures, especially in non-osteoporotic adults; however, randomized controlled trials are needed to rigorously assess fracture benefit.",
keywords = "Adult, Bone mass, Bone mineral density, Growth hormone, Growth hormone deficiency",
author = "Elena Varlamov and Shirley McCartney and Maria Fleseriu",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.coemr.2017.10.001",
language = "English (US)",
volume = "3",
pages = "7--20",
journal = "Current Opinion in Endocrine and Metabolic Research",
issn = "2451-9650",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Growth hormone deficiency and replacement effect on adult bone mass

T2 - A clinical update

AU - Varlamov, Elena

AU - McCartney, Shirley

AU - Fleseriu, Maria

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Patients with growth hormone (GH) deficiency have decreased bone mineral density (BMD) and higher risk of fractures. Younger age, severe GHD, longer period of interruption of GH treatment before achievement of peak bone mass, un-replaced sex steroids or over replacement of glucocorticoid or thyroid deficiencies may contribute to lower BMD in GHD patients. Positive BMD change has been noted in prospective trials after at least a year of GH replacement and may persist for up to 10–15 years with continued treatment. Males and patients with more severe bone loss often respond with better increases in BMD. Growth hormone replacement may decrease risk of fractures, especially in non-osteoporotic adults; however, randomized controlled trials are needed to rigorously assess fracture benefit.

AB - Patients with growth hormone (GH) deficiency have decreased bone mineral density (BMD) and higher risk of fractures. Younger age, severe GHD, longer period of interruption of GH treatment before achievement of peak bone mass, un-replaced sex steroids or over replacement of glucocorticoid or thyroid deficiencies may contribute to lower BMD in GHD patients. Positive BMD change has been noted in prospective trials after at least a year of GH replacement and may persist for up to 10–15 years with continued treatment. Males and patients with more severe bone loss often respond with better increases in BMD. Growth hormone replacement may decrease risk of fractures, especially in non-osteoporotic adults; however, randomized controlled trials are needed to rigorously assess fracture benefit.

KW - Adult

KW - Bone mass

KW - Bone mineral density

KW - Growth hormone

KW - Growth hormone deficiency

UR - http://www.scopus.com/inward/record.url?scp=85051799458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051799458&partnerID=8YFLogxK

U2 - 10.1016/j.coemr.2017.10.001

DO - 10.1016/j.coemr.2017.10.001

M3 - Review article

VL - 3

SP - 7

EP - 20

JO - Current Opinion in Endocrine and Metabolic Research

JF - Current Opinion in Endocrine and Metabolic Research

SN - 2451-9650

ER -